Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Abroad (travel likely)RecruitingPHASE2
Conditions
Multiple Myeloma · Primary Plasma Cell Leukemia · Extramedullary Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Principal Investigator (Chunyan Sun, MD)Jian Xu, MD (Sub-investigator)